{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:39:20Z","timestamp":1793209160764,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad of Spain","doi-asserted-by":"crossref","award":["PID2022-138765OB-I00"],"award-info":[{"award-number":["PID2022-138765OB-I00"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI16\/00460"],"award-info":[{"award-number":["PI16\/00460"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III,Spain","award":["PI19\/01630"],"award-info":[{"award-number":["PI19\/01630"]}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"crossref","award":["BIO\/SA83\/13"],"award-info":[{"award-number":["BIO\/SA83\/13"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The tumor microenvironment (TME) is a major determinant of tumor response to different therapies, especially immunotherapy. Tumors with high CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cell infiltration that respond well to immunotherapy are referred to as \u201chot\u201d tumors, whereas \u201ccold\u201d tumors, with an immunosuppressive microenvironment, respond less effectively to this therapy. Endoglin (CD105) plays a critical role in angiogenesis, and its overexpression has been associated with a poorer prognosis in several types of cancer. This study aims to investigate whether high endoglin levels are associated with a cold microenvironment in tumors. Transgenic mice ubiquitously overexpressing human endoglin (\n                    <jats:italic>ENG<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    ) and wild-type C57BL\/6J mice (WT) were used to analyze the TME in a Lewis Lung Carcinoma (LLC) subcutaneous xenograft model and in a lung cancer model. Tumors developed in\n                    <jats:italic>ENG<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    mice exhibited increased hypoxia, reduced CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cell infiltration and an increased presence of immunosuppressive cells, such as M2 TAMs and Treg, compared to WT tumors. Thus, these tumors can be categorized as cold tumors. In addition, the analysis of the TME and endoglin expression in human lung adenocarcinoma samples showed that cold tumors have higher endoglin levels than hot tumors. These findings suggest that a hypoxic and immunosuppressive microenvironment may contribute to the poorer prognosis of tumors with high levels of this protein. This study highlights the potential of endoglin as a marker to predict the response to immunotherapy and to guide personalized treatment strategies in cancer patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-55711-6","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:05:03Z","timestamp":1781287503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Endoglin (CD105) overexpression is associated with an immunosuppressive tumor microenvironment in murine lung cancer models and human lung adenocarcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Claudia","family":"Ollauri-Ib\u00e1\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Ayuso-\u00cd\u00f1igo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Solano-SC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Perez-Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mu\u00f1oz-F\u00e9lix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Rodr\u00edguez-Barbero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Pericacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"55711_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1084\/jem.133.2.275","volume":"133","author":"J Folkman","year":"1971","unstructured":"Folkman, J., Merler, E., Abernathy, C. & Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133, 275\u2013288. https:\/\/doi.org\/10.1084\/jem.133.2.275 (1971).","journal-title":"J. Exp. Med."},{"key":"55711_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12935-022-02675-y","volume":"22","author":"H Huang","year":"2022","unstructured":"Huang, H. et al. Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer. Cancer Cell. Int. 22, 261. https:\/\/doi.org\/10.1186\/s12935-022-02675-y (2022).","journal-title":"Cancer Cell. Int."},{"key":"55711_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2022.02.002","volume":"166","author":"J Remon","year":"2022","unstructured":"Remon, J. et al. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. Eur. J. Cancer. 166, 112\u2013125. https:\/\/doi.org\/10.1016\/j.ejca.2022.02.002 (2022).","journal-title":"Eur. J. Cancer"},{"key":"55711_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/379088a0","volume":"379","author":"TG Graeber","year":"1996","unstructured":"Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88\u201391. https:\/\/doi.org\/10.1038\/379088a0 (1996).","journal-title":"Nature"},{"key":"55711_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/sj.bjc.6605690","volume":"102","author":"M Ilie","year":"2010","unstructured":"Ilie, M. et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br. J. Cancer. 102, 1627\u20131635. https:\/\/doi.org\/10.1038\/sj.bjc.6605690 (2010).","journal-title":"Br. J. Cancer"},{"key":"55711_CR6","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.cell.2018.11.006","volume":"175","author":"J Wolchok","year":"2018","unstructured":"Wolchok, J. Putting the Immunologic Brakes on Cancer. Cell 175, 1452\u20131454. https:\/\/doi.org\/10.1016\/j.cell.2018.11.006 (2018).","journal-title":"Cell"},{"key":"55711_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060 (2018).","journal-title":"Science"},{"key":"55711_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","volume":"17","author":"LG Paz-Ares","year":"2022","unstructured":"Paz-Ares, L. G. et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J. Thorac. Oncol. 17, 289\u2013308. https:\/\/doi.org\/10.1016\/j.jtho.2021.09.010 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"55711_CR9","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.2217\/fon-2021-1486","volume":"18","author":"D Schadendorf","year":"2022","unstructured":"Schadendorf, D. et al. STARBOARD: encorafenib\u2009+\u2009binimetinib\u2009+\u2009pembrolizumab for first-line metastatic\/unresectable BRAF V600-mutant melanoma. Future Oncol. 18, 2041\u20132051. https:\/\/doi.org\/10.2217\/fon-2021-1486 (2022).","journal-title":"Future Oncol."},{"key":"55711_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112136","author":"LJ Brown","year":"2024","unstructured":"Brown, L. J. et al. Site-specific response and resistance patterns in patients with advanced non-small-cell lung cancer treated with first-line systemic therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16112136 (2024).","journal-title":"Cancers (Basel)"},{"key":"55711_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3892\/ol.2024.14538","volume":"28","author":"Z Xu","year":"2024","unstructured":"Xu, Z. et al. Real\u2013world evidence of advanced non\u2013small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy. Oncol. Lett. 28, 405. https:\/\/doi.org\/10.3892\/ol.2024.14538 (2024).","journal-title":"Oncol. Lett."},{"key":"55711_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/ijc.32889","volume":"147","author":"E De Guillebon","year":"2020","unstructured":"De Guillebon, E. et al. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. Int. J. Cancer. 147, 1509\u20131518. https:\/\/doi.org\/10.1002\/ijc.32889 (2020).","journal-title":"Int. J. Cancer"},{"key":"55711_CR13","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson, N. M. & Simon, M. C. Tumor Microenvironment. Curr. Biol. 30, R921\u2013R925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081 (2020).","journal-title":"Curr. Biol."},{"key":"55711_CR14","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/cancers13071552","volume":"13","author":"C Ollauri-Ib\u00e1\u00f1ez","year":"2021","unstructured":"Ollauri-Ib\u00e1\u00f1ez, C., Ayuso-\u00cd\u00f1igo, B. & Pericacho, M. Hot and cold tumors: is endoglin (CD105) a potential target for vessel normalization? Cancers (Basel). 13, 1552. https:\/\/doi.org\/10.3390\/cancers13071552 (2021).","journal-title":"Cancers (Basel)"},{"key":"55711_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.bioactmat.2023.06.021","volume":"29","author":"T Colombani","year":"2023","unstructured":"Colombani, T. et al. Hypoxia-inducing cryogels uncover key cancer-immune cell interactions in an oxygen-deficient tumor microenvironment. Bioact Mater. 29, 279\u2013295. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.06.021 (2023).","journal-title":"Bioact Mater."},{"key":"55711_CR16","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1038\/s41388-023-02869-2","volume":"42","author":"P Fan","year":"2023","unstructured":"Fan, P. et al. Alleviating hypoxia to improve cancer immunotherapy. Oncogene 42, 3591\u20133604. https:\/\/doi.org\/10.1038\/s41388-023-02869-2 (2023).","journal-title":"Oncogene"},{"key":"55711_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. da, Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy. Cancer Cell. 35, 238\u2013255 https:\/\/doi.org\/10.1016\/j.ccell.2019.01.003 (2019).","journal-title":"Cancer Cell."},{"key":"55711_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10456-008-9101-9","volume":"11","author":"P ten Dijke","year":"2008","unstructured":"ten Dijke, P., Goumans, M. J. & Pardali, E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 11, 79\u201389. https:\/\/doi.org\/10.1007\/s10456-008-9101-9 (2008).","journal-title":"Angiogenesis"},{"key":"55711_CR19","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/j.jtha.2023.06.007","volume":"21","author":"E Rossi","year":"2023","unstructured":"Rossi, E. & Bernabeu, C. Novel vascular roles of human endoglin in pathophysiology. J. Thromb. Haemost. 21, 2327\u20132338. https:\/\/doi.org\/10.1016\/j.jtha.2023.06.007 (2023).","journal-title":"J. Thromb. Haemost."},{"key":"55711_CR20","first-page":"2283","volume":"31","author":"F Nassiri","year":"2011","unstructured":"Nassiri, F. et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res. 31, 2283\u20132290 (2011).","journal-title":"Anticancer Res."},{"key":"55711_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1517\/14728222.2013.758716","volume":"17","author":"M Paauwe","year":"2013","unstructured":"Paauwe, M., ten Dijke, P. & Hawinkels, L. J. A. C. Endoglin for tumor imaging and targeted cancer therapy. Expert Opin. Ther. Targets. 17, 421\u2013435. https:\/\/doi.org\/10.1517\/14728222.2013.758716 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"key":"55711_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10456-019-09703-y","volume":"23","author":"C Ollauri-Ib\u00e1\u00f1ez","year":"2020","unstructured":"Ollauri-Ib\u00e1\u00f1ez, C. et al. Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis. Angiogenesis 23, 231\u2013247. https:\/\/doi.org\/10.1007\/s10456-019-09703-y (2020).","journal-title":"Angiogenesis"},{"key":"55711_CR23","doi-asserted-by":"publisher","first-page":"e110365","DOI":"10.1371\/journal.pone.0110365","volume":"9","author":"B Oujo","year":"2014","unstructured":"Oujo, B. et al. L-Endoglin overexpression increases renal fibrosis after unilateral ureteral obstruction. PLoS One. 9, e110365. https:\/\/doi.org\/10.1371\/journal.pone.0110365 (2014).","journal-title":"PLoS One"},{"key":"55711_CR24","doi-asserted-by":"publisher","first-page":"30527","DOI":"10.18632\/oncotarget.25668","volume":"9","author":"F Janker","year":"2018","unstructured":"Janker, F., Weder, W., Jang, J. H. & Jungraithmayr, W. Preclinical, non-genetic models of lung adenocarcinoma: a comparative survey. Oncotarget 9, 30527\u201330538. https:\/\/doi.org\/10.18632\/oncotarget.25668 (2018).","journal-title":"Oncotarget"},{"key":"55711_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.devcel.2011.07.001","volume":"21","author":"A Armulik","year":"2011","unstructured":"Armulik, A., Genov\u00e9, G. & Betsholtz, C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell. 21, 193\u2013215. https:\/\/doi.org\/10.1016\/j.devcel.2011.07.001 (2011).","journal-title":"Dev. Cell."},{"key":"55711_CR26","doi-asserted-by":"publisher","first-page":"R1161","DOI":"10.1016\/j.cub.2016.09.043","volume":"26","author":"PP Wong","year":"2016","unstructured":"Wong, P. P., Bodrug, N. & Hodivala-Dilke, K. M. Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment. Curr. Biol. 26, R1161\u2013R1166. https:\/\/doi.org\/10.1016\/j.cub.2016.09.043 (2016).","journal-title":"Curr. Biol."},{"key":"55711_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2014.10.015","volume":"27","author":"PP Wong","year":"2015","unstructured":"Wong, P. P. et al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell. 27, 123\u2013137. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.015 (2015).","journal-title":"Cancer Cell."},{"key":"55711_CR28","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/2326-6066.CIR-18-0865","volume":"7","author":"M Di Tacchio","year":"2019","unstructured":"Di Tacchio, M. et al. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunol. Res. 7, 1910\u20131927. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0865 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"55711_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41571-019-0181-9","volume":"16","author":"EA Kuczynski","year":"2019","unstructured":"Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S. & Reynolds, A. R. Vessel co-option in cancer. Nat. Rev. Clin. Oncol. 16, 469\u2013493. https:\/\/doi.org\/10.1038\/s41571-019-0181-9 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"55711_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/path.4845","volume":"241","author":"VL Bridgeman","year":"2017","unstructured":"Bridgeman, V. L. et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J. Pathol. 241, 362\u2013374. https:\/\/doi.org\/10.1002\/path.4845 (2017).","journal-title":"J. Pathol."},{"key":"55711_CR31","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1158\/0008-5472.CAN-22-0325","volume":"82","author":"J Boumelha","year":"2022","unstructured":"Boumelha, J. et al. An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations. Cancer Res. 82, 3435\u20133448. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0325 (2022).","journal-title":"Cancer Res."},{"key":"55711_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"55711_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & G\u00f6genur, I. Cytotoxic CD8\u2009+\u2009T cells in cancer and cancer immunotherapy. Br. J. Cancer. 124, 359\u2013367. https:\/\/doi.org\/10.1038\/s41416-020-01048-4 (2021).","journal-title":"Br. J. Cancer"},{"key":"55711_CR34","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","volume":"6","author":"JA Trujillo","year":"2018","unstructured":"Trujillo, J. A., Sweis, R. F., Bao, R. & Luke, J. J. T Cell\u2013Inflamed versus Non-T Cell\u2013Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol. Res. 6, 990\u20131000. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0277 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"55711_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","volume":"5","author":"SIS Mosely","year":"2017","unstructured":"Mosely, S. I. S. et al. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunol. Res. 5, 29\u201341. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0114 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"55711_CR36","doi-asserted-by":"publisher","first-page":"eabm8780","DOI":"10.1126\/sciadv.abm8780","volume":"8","author":"E Mugarza","year":"2022","unstructured":"Mugarza, E. et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci. Adv. 8, eabm8780. https:\/\/doi.org\/10.1126\/sciadv.abm8780 (2022).","journal-title":"Sci. Adv."},{"key":"55711_CR37","doi-asserted-by":"publisher","first-page":"689286","DOI":"10.3389\/fcell.2021.689286","volume":"9","author":"SL Ciummo","year":"2021","unstructured":"Ciummo, S. L. et al. The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs. Front. Cell. Dev. Biol. 9, 689286. https:\/\/doi.org\/10.3389\/fcell.2021.689286 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"55711_CR38","doi-asserted-by":"publisher","first-page":"9830","DOI":"10.1021\/acsnano.8b00967","volume":"12","author":"L Shen","year":"2018","unstructured":"Shen, L. et al. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers. ACS Nano. 12, 9830\u20139841. https:\/\/doi.org\/10.1021\/acsnano.8b00967 (2018).","journal-title":"ACS Nano"},{"key":"55711_CR39","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fphar.2019.01371","volume":"10","author":"S Wang","year":"2019","unstructured":"Wang, S. et al. XIAOPI Formula Inhibits Breast Cancer Stem Cells via Suppressing Tumor-Associated Macrophages\/C-X-C Motif Chemokine Ligand 1 Pathway. Front. Pharmacol. 10, 1371. https:\/\/doi.org\/10.3389\/fphar.2019.01371 (2019).","journal-title":"Front. Pharmacol."},{"key":"55711_CR40","first-page":"3410","volume":"7","author":"F Tanaka","year":"2001","unstructured":"Tanaka, F. et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin. Cancer Res. 7, 3410\u20133415 (2001).","journal-title":"Clin. Cancer Res."},{"key":"55711_CR41","first-page":"39","volume":"37","author":"Y Yao","year":"2007","unstructured":"Yao, Y. et al. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann. Clin. Lab. Sci. 37, 39\u201348 (2007).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"55711_CR42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1440-1789.2005.00632.x","volume":"25","author":"Y Yao","year":"2005","unstructured":"Yao, Y., Kubota, T., Takeuchi, H. & Sato, K. Prognostic significance of microvessel density determined by an anti-CD105\/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 25, 201\u2013206. https:\/\/doi.org\/10.1111\/j.1440-1789.2005.00632.x (2005).","journal-title":"Neuropathology"},{"key":"55711_CR43","first-page":"856","volume":"59","author":"S Kumar","year":"1999","unstructured":"Kumar, S. et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 59, 856\u2013861 (1999).","journal-title":"Cancer Res."},{"key":"55711_CR44","doi-asserted-by":"publisher","first-page":"43799","DOI":"10.1074\/jbc.M207160200","volume":"277","author":"T S\u00e1nchez-Elsner","year":"2002","unstructured":"S\u00e1nchez-Elsner, T., Botella, L. M., Velasco, B., Langa, C. & Bernab\u00e9u, C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 277, 43799\u201343808. https:\/\/doi.org\/10.1074\/jbc.M207160200 (2002).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55711-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:30:17Z","timestamp":1787787017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55711-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55711"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55711-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6611853\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26896"}}